M3-JIA: Making Mindfulness Matter for Children With JIA (NCT06376149)
A Pilot Randomized-controlled Trial Evaluating the Efficacy of a Live-Online Mindfulness-Based Intervention: The Making Mindfulness Matter© in Children With Juvenile Idiopathic Arthritis Study
🩺 Plain-English Summary (8th-Grade Level)
The investigator will evaluate the efficacy of M3©, an intervention for patients with JIA and their caregivers. Children with Juvenile arthritis and their parents will attend an 8 week online program called Making Mindfulness Matter (M3). This is a facilitator-led program that integrates knowledge and skills related to mindfulness, social-emotional learning, neuroscience, and positive psychology to promote coping and resiliency for children and families in context of the challenges of pediatric chronic disease. The child program is designed for children 4-12 years of age, with each lesson including a variety of concrete ways to teach children skills based on their age/developmental level.
Who can join: Review the eligibility criteria below.
Location: McMaster Children's Hospital, — Hamilton, Ontario
Age range: 4 Years to 12 Years
🧪 Interventions in This Study
- M3 Intervention group (BEHAVIORAL)
- M3 Waitlist Group (BEHAVIORAL)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (3 Sites)
- McMaster Children's Hospital, — Hamilton, Ontario
- LHSC Children' Hosptial — London, Ontario
- Sickids — Toronto, Ontario
📞 Contact the Study Coordinator
Phone: (519) 685-8500
Email: sarah.wells@lhsc.on.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Juvenile Idiopathic Arthritis
- An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis — Little Rock, Arkansas
- Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis. — Phoenix, Arizona
- A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS) — San Miguel de Tucumán, Tucumán Province
- A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis — Rosario,
- UCAN CAN-DU: Canada-Netherlands Personalized Medicine Network in Childhood Arthritis and Rheumatic Disease — Calgary, Alberta
Explore by condition: All Juvenile Idiopathic Arthritis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.